Page 1 | Search Results | Blood Advances | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

Annette von Drygalski, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan U. Lattimore, Frank W. G. Leebeek, Wolfgang A. Miesbach, Michael Recht, Robert Gut, Ricardo Dolmetsch, Paul E. Monahan, Sandra Le Quellec, Steven W. Pipe

Blood Adv (2023) 7 (19): 5671–5679.

https://doi.org/10.1182/bloodadvances.2022008886

Published: 2023

Includes: Supplemental data

Journal Articles

Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B

Manfred Schmidt, Graham R. Foster, Michiel Coppens, Hauke Thomsen, Ricardo Dolmetsch, Liesbeth Heijink, Paul E. Monahan, Steven W. Pipe

Blood Adv (2023) 7 (17): 4966–4969.

https://doi.org/10.1182/bloodadvances.2023009876

Published: 2023

Includes: Supplemental data

Journal Articles

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Rebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, Tiffany Chang, Sammy Chebon, Michelle Y. Doral, Stacy E. Croteau, Thierry Lambert, Christine L. Kempton, Steven W. Pipe, Richard H. Ko, Benjamin Trzaskoma, Christophe Dhalluin, Nives Selak Bienz, Markus Niggli, Michaela Lehle, Ido Paz-Priel, Guy Young, Víctor Jiménez-Yuste

Blood Adv (2022) 6 (24): 6140–6150.

https://doi.org/10.1182/bloodadvances.2022007458

Published: 2022

Includes: Supplemental data

Journal Articles

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W. G. Leebeek, Wolfgang Miesbach, Michael Recht, Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe

Blood Adv (2019) 3 (21): 3241–3247.

https://doi.org/10.1182/bloodadvances.2019000811

Published: 2019

Includes: Supplemental data

Journal Articles

Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies

Angela C. Weyand, Veronica H. Flood, Jordan A. Shavit, Steven W. Pipe

Blood Adv (2019) 3 (18): 2748–2750.

https://doi.org/10.1182/bloodadvances.2019000656

Published: 2019

NARROW

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies

Email alerts

ASH Publications

American Society of Hematology

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only